Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
19 NC counties are under alert, including Wake, Durham, Orange, Nash, and Franklin counties.
Program
On WRAL at 5: Multiple reports of flooding and storm damage. Where weâre seeing trouble spots in the WRAL Storm Tracker
Program
On WRAL at 6: WRAL Investigates why a school took nearly two years to report alleged abuse to law enforcement and parents.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bolt Biotherapeutics Inc
(NQ:
BOLT
)
0.7300
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bolt Biotherapeutics Inc
< Previous
1
2
3
4
Next >
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 05, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
November 07, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Looking Into Bolt Biotherapeutics's Return On Capital Employed
March 30, 2023
Via
Benzinga
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
October 23, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
October 18, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
October 17, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
October 16, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
October 02, 2023
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not...
Via
Benzinga
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
September 28, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
September 12, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Participate in September Investor Conferences
September 05, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
August 03, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
July 31, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
May 25, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
May 12, 2023
Via
Benzinga
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
April 26, 2023
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
March 30, 2023
Via
Benzinga
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
March 29, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
March 14, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
February 28, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at February Investor Conferences
February 01, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
December 14, 2022
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
November 07, 2022
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
November 01, 2022
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.